Synonym
ONO-2952; ONO2952; ONO 2952
IUPAC/Chemical Name
(S)-1-(1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',9'-dihydrospiro[cyclopropane-1,4'-pyrido[3,4-b]indol]-2'(3'H)-yl)ethan-1-one
InChi Key
ZBQMTQGDBFZUBG-NRFANRHFSA-N
InChi Code
CC(N(C[15:S=N]HC[19]()=CC=C(Cl)C=C@19OC)CC[2](C[7]()=C(@15)NC[14]=C@8C(F)=CC=C@14)CC@3)=O
SMILES Code
CC(N([C@H]1C2=CC=C(Cl)C=C2OC)CC3(C4=C1NC5=C4C(F)=CC=C5)CC3)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
398.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Frankle WG, Narendran R, Wood AT, Suto F, Himes ML, Kobayashi M, Ohno T, Yamauchi A, Mitsui K, Duffy K, Bruce M. Brain translocator protein occupancy by ONO-2952 in healthy adults: A Phase 1 PET study using [(11) C]PBR28. Synapse. 2017 Feb 28. doi: 10.1002/syn.21970. [Epub ahead of print] PubMed PMID: 28245513.
2: Mitsui K, Niwa T, Kawahara Y, Morimoto N, Ohmoto K, Kato M, Yamaura Y, Yoshimoto N, Suna H, Katsumata S. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Dec;99:51-66. doi: 10.1016/j.neuropharm.2015.07.011. Epub 2015 Jul 17. PubMed PMID: 26189762.
3: Suto F, Wood AT, Kobayashi M, Komaba J, Duffy K, Bruce M. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers. Clin Ther. 2015 Sep;37(9):2071-84. doi: 10.1016/j.clinthera.2015.07.010. Epub 2015 Aug 4. PubMed PMID: 26249232.
4: Mitsui K, Morimoto N, Niwa T, Yamaura Y, Ohba H, Tsukada H, Katsumata S. Quantification of ONO-2952 Occupancy of 18-kDaTranslocator Protein in Conscious Monkey Brains using Positron Emission Tomography. J Pharmacol Exp Ther. 2017 Mar;360(3):457-465. doi: 10.1124/jpet.116.238568. Epub 2016 Dec 16. PubMed PMID: 27986860.
5: Whitehead WE, Duffy K, Sharpe J, Nabata T, Bruce M. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Jan;45(1):14-26. doi: 10.1111/apt.13839. Epub 2016 Nov 7. PubMed PMID: 27910150.
6: Nee J, Lembo A. Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2017 Apr;45(7):1004-1005. doi: 10.1111/apt.13920. PubMed PMID: 28256084.
7: Whitehead WE, Duffy K, Sharpe J, Nabata T, Bruce M. Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea - authors' reply. Aliment Pharmacol Ther. 2017 Apr;45(7):1005. doi: 10.1111/apt.13957. PubMed PMID: 28256085.
